German Health Institute Reports Minor Added Benefit for Guselkumab in Specific Chronic Crohn’s Disease Subgroups

IQWiG assessment finds guselkumab offers a minor added benefit for Crohn’s disease patients switching biologics, though no added benefit for ulcerative colitis.

By: AXL Media

Published: Mar 28, 2026, 5:15 AM EDT

Source: Information for this report was sourced from Institute for Quality and Efficiency in Health Care

Evaluating Monoclonal Antibody Efficacy in Bowel Disorders

The recent assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) marks a significant step in defining the clinical role of guselkumab within the European pharmaceutical market. As a human monoclonal antibody, guselkumab was approved in 2025 to address moderately to severely active cases of ulcerative colitis and Crohn’s disease. The German health authorities utilized a randomized controlled trial to determine if the drug provides a measurable improvement over existing treatment regimens. This evaluation is part of a broader regulatory effort to ensure that new, high-cost therapies offer tangible advantages to patients before they are fully integrated into standard care protocols.

Comparative Limitations in Ulcerative Colitis Treatment

In the specific context of ulcerative colitis, the IQWiG analysis focused on patients who were either intolerant to or had failed to respond to conventional therapies. The randomized controlled trial provided a direct comparison between guselkumab and golimumab, a long-standing treatment option. While the data suggested some positive trends in general morbidity and health-related quality of life, the institute concluded that these gains did not reach the threshold of clinical relevance. Consequently, for this specific patient group, guselkumab was not found to offer an added benefit over the current medical standard, maintaining the status quo for colitis management.

Identifying Success in Refractory Crohn’s Disease

The findings were notably different for patients suffering from Crohn’s disease, particularly those who have already undergone treatment with other biologic agents. For this subgroup, the IQWiG assessment compared guselkumab directly with ustekinumab. The results indicated that for patients needing a treatment switch after previous biologic failure, guselkumab provided a statistically significant improvement in health-related quality of life. This led the institute to formally recognize a "hint of minor added benefit," providing a clinical justification for physicians to consider the switch in complex, treatment-resistant cases.